Adept adds two support staff
For expanding range of data acquisition products
Henrique da Silva will concentrate on DAQ sales. He has an MSc in Electronics & Computer Engineering.
Elizabeth Northrop (Lilly) will focus on technical support. She has an MEng in Systems Engineering.
With offices in the UK, Germany and throughout the Nordic region, Adept Scientific is a supplier of software and hardware products for research, scientific, engineering and technical applications on desktop computers.
You may also like
Digital
Shilpa Biologicals launches PartnerPower real-time visibility platform for biologics CDMO operations
The digital data fabric links R&D, analytical development and GMP manufacturing, replacing periodic reporting with continuous audit-ready transparency aligned to FDA, EMA and PMDA expectations
Regulatory
Pheno Therapeutics gains FDA IND clearance for first-in-class GPR17 antagonist PTD802 in MS
The clearance enables a first-in-human trial of the UCB-licensed remyelination candidate, marking the first GPR17 programme to reach clinical development for multiple sclerosis and related demyelinating diseases
Research & Development
Promega UK Launches Lumit Cell Proliferation Assay (Human Ki-67) for rapid, wash-free detection of a key proliferation marker
New homogeneous, plate-based assay enables researchers to track hKi-67 in a simple add-and-read format, delivering robust and reproducible results in less time
Research & Development
BioArctic and Lilly sign $30m collaboration combining BrainTransporter with Lilly neurodegeneration asset
The deal, worth up to $800m including milestones, marks BioArctic's fourth BrainTransporter partnership — joining existing collaborations with Eisai, Bristol Myers Squibb and Novartis to advance brain-targeted biologics delivery
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
Mabion and Oddifact to explore orphan drug potential of MabionCD20 through new collaboration
Mabion has signed a letter of intent with Oddifact to reposition its Phase III-stage CD20 monoclonal antibody candidate for rare disease indications, leveraging AI-driven orphan drug identification and existing manufacturing expertise